| 2019-LOW-68704 | |
| Researchers at Purdue University have developed a method for making drug conjugates through antifibrotic ligand-targeting. Currently, Cancer-Associated Fibroblasts (CAFs) tend to progressively resist pharmacotherapies. CAFs are responsible for spontaneous cell motility, growth of tumors, and often cancer relapse in patients. Aiming to provide sensitive patient care, the Purdue University drug conjugate reduces immunosuppression and chemoresistance. The drug can be used for treating fibrosis, rheumatoid arthritis, wounds, and cancers. Epithelial carcinomas can now be detected non-invasively, and when tested in mice ninety-eight percent of fibroblast cells were accurately detected. In addition, this conjugate-based method can be used to prevent and treat idiopathic pulmonary fibrosis disease, which remains untreated in one hundred twenty-eight thousand people. Advantages: -Ligand-targeted -Enhanced pharmacotherapy -Precise identification of tumor microenvironments Potential Applications: -Imaging for cancer and inflammatory diseases -Cancer therapy |
|
|
|
|
Jul 29, 2022
NATL-Patent
United States
(None)
(None)
Jan 29, 2021
PCT-Patent
WO
(None)
(None)
Jan 29, 2021
NATL-Patent
Europe
(None)
(None)
Jan 31, 2020
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
